Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 24, 2013. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 575,000 Ordinary Shares of 25 pence each.
- Purchase Date: May 24, 2013.
- Price Range: Highest price paid was 1,750.0 pence per share; lowest price paid was 1,727.0 pence per share.
- Treasury Holdings (Settled): 500,092,012 shares (9.21% of total issued share capital).
- Treasury Holdings (Including Unsettled): 502,067,012 shares (10.19% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,928,014,023 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 575,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.19% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification regarding the Financial Conduct Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (500,092,012 settled vs. 502,067,012 including unsettled).
- Confirm the denominator for voting rights calculations is 4,928,014,023 shares (excluding Treasury).
- Check the price paid per share against market prices on May 24, 2013 (range: 1,727.0 to 1,750.0 pence).
- Review the remaining authorization for share buybacks following this transaction.